Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Envisions Drug Price Arbitration For Part D

This article was originally published in The Pink Sheet Daily

Executive Summary

Approaches for HHS to become involved in drug price negotiations between Medicare Part D plan sponsors and manufacturers were outlined by HHS Assistant Secretary for Planning and Evaluation Richard Frank at a policy conference, although current law would need to be revised to allow it.

You may also be interested in...



Trump Makes A Nasty News Day For Pharma – But What Will It Really Mean?

President-elect threatens a government bidding process to control drug pricing in his first post-election press conference.

HHS Raises Profile In Drug Costs Discussion

On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.

Pricing, Pediatrics, Pot: 21st Century Cures Amendments

Committee members didn’t even vote on any amendments besides the manager’s package, but proposals floated and withdrawn offer glimpse at potential fights to come.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel